Kits and methods to distinguish false labor and true labor

1. A method, comprising:

obtaining a sample from a pregnant female experiencing symptoms associated with false labor and true labor; and

measuring in the sample for abundance of:

(i) tissue factor (TF), ICOS Ligand (B7-H2), VPS10 Domain Containing Receptor SorCS2 (SORC2), and Plasma Protease C1 Inhibitor (C1-Esterase Inhibitor); or

(ii) TF, Ras-related Nuclear protein (Ran), Inosine-5′-monophosphate dehydrogenase (IMDH1), and Phosphoglycerate mutase 1 (PGAM1).

2. The method of claim 1 , comprising:

measuring TF, B7-H2, SORC2, C1-Esterase Inhibitor.

3. The method of claim 1 (i) or claim 2 , further comprising calculating a rate of change of abundance of TF, B7-H2, SORC2, and C1-Esterase Inhibitor between two samples obtained from the same pregnant female at two different times, and

using the calculated rate of change of abundance to identify whether the pregnant female is in true labor or false labor.

4. The method of claim 3 , wherein the calculating of the rate of change of abundance of TF, B7-H2, SORC2, and C1-Esterase Inhibitor is the formula:

(Abundance T2 −Abundance T1 )/(GA T2 −GA T1 ), wherein GA refers to gestational age and can be measured in weeks, wherein T 1 refers to a first time-point and a T 2 refers to a second, later time-point.

5. The method of claim 4 , wherein:

(a) GA T2 and GA T1 are between 33 and 40 weeks; and/or

(b) the rate of change of abundance is used to calculate a true labor score (1), according to the formula:

true labor score(1)=4.4* S (B7-H2) −5.9* S (Sorc2) −0.5* S (TF) −0.03* S (C1-Esterase Inhibitor )+1.1,

or

true labor score(1)=4.422* S (B7-H2) −5.981* S (Sorc2) −0.538* S (TF) −0.033* S (C1-Esterase Inhibitor) +1.134,

wherein S refers to the rate of change of abundance.

6. The method of claim 1 , wherein:

the sample obtained from a pregnant female is collected between 33 and 40 weeks of the female's pregnancy; and/or

the sample is obtained when the pregnant female is experiencing symptoms associated with false labor and true labor; and/or

the symptoms are contractions; and/or

the samples are plasma or serum samples.

7. The method of claim 1 (ii) or 2 , further comprising calculating changes in abundance (CA) of TF, Ran, IMDH1, and PGAM1 as compared to a value derived from a reference population that has not experienced true labor; and

using the calculated change in abundance to identify whether the pregnant female is in true labor or false labor.

8. The method of claim 7 , comprising:

calculating a true labor score(2), wherein CA TF , CA Ran , CA IMDH1 , and CA PGAM1 are used in a Linear Discriminant Analysis Model; and/or

analysis of true labor score(2);

wherein the true labor score(2) comprises two threshold values, X and Y,

wherein a true labor score(2)≤X denotes that the pregnant female is in false labor, and a true labor score(2)>Y denotes that the pregnant female is in true labor; and

using the calculated true labor score(2) to identify whether the pregnant female is in true labor or false labor.

9. A method, comprising:

obtaining a sample from a pregnant female experiencing symptoms associated with false labor and true labor; and

measuring in the sample a level or an amount of each of:

(i) tissue factor (TF), ICOS Ligand (B7-H2), VPS10 Domain Containing Receptor SorCS2 (SORC2), and Plasma Protease C1 Inhibitor (C1-Esterase Inhibitor); or

(ii) TF, Ras-related Nuclear protein (Ran), Inosine-5′-monophosphate dehydrogenase (IMDH1), and Phosphoglycerate mutase 1 (PGAM1).

10. The method of claim 9 , comprising measuring the level or amount of each of TF, B7-H2, SORC2, C1-Esterase Inhibitor Ran, IMDH1, and PGAM1.

11. The method of claim 9 (i) or claim 10 , further comprising calculating a rate of change of level or amount of TF, B7-H2, SORC2, and C1-Esterase Inhibitor between two samples obtained from the same pregnant female at two different times, and

using the calculated rate of change of level or amount to identify whether the pregnant female is in true labor or false labor.

12. The method of claim 11 , wherein the calculating of the rate of change of level or amount of TF, B7-H2, SORC2, and C1-Esterase Inhibitor is the formula:

(AbundanceT2−Abundance T1 )/(GAT2−GA T1 ), wherein GA refers to gestational age and can be measured in weeks, wherein T 1 refers to a first time-point and a T 2 refers to a second, later time-point.

13. The method of claim 12 , wherein:

(a) GA T2 and GA T1 are between 33 and 40 weeks; and/or

(b) the rate of change of level or amount is used to calculate a true labor score (1), according to the formula:

true labor score(1)=4.4* S (B7-H2) −5.9* S (Sorc2) −0.5* S (TF) −0.03* S (C1-Esterase Inhibitor) +1.1,

or

true labor score(1)=4.422* S (B7-H2) −5.981* S (sorc2) −0.538* S (TF) −0.033* S (C1-Esterase Inhibitor) +1.134,

wherein S refers to the rate of change of level or amount.

14. The method of claim 9 , wherein:

the sample obtained from a pregnant female is collected between 33 and 40 weeks of the female's pregnancy; and/or

the sample is obtained when the pregnant female is experiencing symptoms associated with false labor and true labor; and/or

the symptoms are contractions; and/or

the samples are plasma or serum samples.

15. The method of claim 9 (ii) or 10 , further comprising calculating changes in level or amount (CA) of TF, Ran, IMDH1, and PGAM1 as compared to a value derived from a reference population that has not experienced true labor; and

using the calculated change in level or amount to identify whether the pregnant female is in true labor or false labor.

16. The method of claim 14 , comprising:

calculating a true labor score(2), wherein CA TF , CA Ran , CA IMDH1 , and CA PGAM1 are used in a Linear Discriminant Analysis Model; and/or

analysis of true labor score(2);

wherein the true labor score(2) comprises two threshold values, X and Y,

wherein a true labor score(2)≤X denotes that the pregnant female is in false labor, and a true labor score(2)>Y denotes that the pregnant female is in true labor; and

using the calculated true labor score(2) to identify whether the pregnant female is in true labor or false labor.

17. A method, comprising:

obtaining a sample from a pregnant female experiencing symptoms associated with false labor and true labor; and

measuring in the sample abundance of tissue factor (TF) in combination with

(i) ICOS Ligand (B7-H2) and/or VPS10 Domain Containing Receptor SorCS2 (SORC2); or

(ii) Ras-related Nuclear protein (Ran), Inosine-5′-monophosphate dehydrogenase (IMDH1), and/or Phosphoglycerate mutase 1 (PGAM1).

18. The method of claim 17 , comprising:

(a) assessing TF in combination with B7-H2, SORC2, and C1-Esterase Inhibitor; or

(b) assessing TF in combination with Ran, IMDH1, and PGAM1; or

(c) both (a) and (b).

19. The method of claim 17 , wherein:

the sample obtained from a pregnant female is collected between 33 and 40 weeks of the female's pregnancy; and/or

the sample is obtained when the pregnant female is experiencing symptoms associated with false labor and true labor; and/or

the symptoms are contractions; and/or

the samples are plasma or serum samples.